Pasithea Therapeutics announced FDA clearance of its Investigational New Drug (IND) application for PAS-004, a next-gen oral MEK inhibitor, to treat cutaneous neurofibromas (cNF) associated with neurofibromatosis type 1 (NF1). This clearance allows Pasithea to start a randomized, placebo-controlled Phase 2 clinical trial in the U.S. cNF affects over 95% of NF1 patients and currently has no FDA-approved systemic treatments. PAS-004 aims to address this unmet need, potentially becoming the first FDA-approved systemic therapy for cNF, impacting an estimated 80,000 U.S. patients with moderate to severe disease.
Pasithea Therapeutics' FDA clearance for PAS-004 in treating neurofibromatosis type 1 offers context for health sector performance. For readers following health stocks, here is Pluang's market snapshot as of Nov 03, 2026 19:02 WIB: Among 150 priced US health stocks, 74 rose and 69 fell. BioNTech SE (BNTX) stood out with a 2.94% gain and 100% buy order activity, contrasting with Travere Therapeutics (TVTX) which declined by 3.98%. Aurora Cannabis (ACB) also gained 4.27%, with a typical hold time of 26 days on Pluang.
Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...
Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...
Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...
Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...
Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...
